• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·PRAY.JK
Share

PT Famon Awal Bros Sedaya Tbk Stocks

IDR 720Last Updated 18.09.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

IDR 623.99M

IDR 720
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Famon Awal Bros Sedaya Tbk operates a network of hospitals throughout Indonesia. The company delivers a broad spectrum of specialized medical services, encompassing cardiovascular treatment, orthopedic sports medicine, trauma care, oncology (cancer treatment), neurological and brain health, ophthalmology, maternal and pediatric services, and urology. Additionally, it offers clinical laboratory analysis, in-home care, medical transportation, and digital consultation services, among other diverse healthcare provisions. Founded in 1997 and headquartered in Kemayoran, Indonesia, PT Famon Awal Bros Sedaya Tbk is a subsidiary of PT Famon Obor Maju.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PRAY.JK is 1200 and suggests 66.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 14:33

Where to Invest $10,000 to Profit from a Decline in AI: Put Options and Hedge Stocks

22.09.2026 14:12

Morgan Stanley has updated its list of the top 15 stocks for the year. Last year's picks outperformed the S&P 500.

22.09.2026 13:48

Burry bet on copper for AI. Why did he buy shares in the little-known company Ero?

22.09.2026 12:25

Oninvest Index: Small-cap data center stocks rose 48%. What will drive this growth?

22.09.2026 12:03

Alibaba has unveiled "China's most powerful AI chip." Is this a threat to Nvidia?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026